Loading...
•
Jun 30, 2024
Prestige Consumer Q1 2025 Earnings Report
Prestige Consumer's Q1 2025 results exceeded expectations, driven by strong revenue and cash generation.
Key Takeaways
Prestige Consumer Healthcare reported first quarter fiscal 2025 results with revenue of $267.1 million and EPS of $0.98. The company reaffirmed its full-year fiscal 2025 revenue, earnings, and cash flow outlook. Strong cash generation allowed for debt reduction and share repurchases.
Revenue of $267.1 million exceeded expectations.
EPS reached $0.98 and adjusted EPS was $0.90.
Cash from operations increased by 13.9% year-over-year to $54.8 million.
The company reaffirmed its full-year fiscal 2025 outlook for revenue, earnings, and cash flow.
Prestige Consumer
Prestige Consumer
Prestige Consumer Revenue by Segment
Revenue by Segment
North American OTC Healthcare Revenue
CapyFin.comInternational OTC Healthcare Revenue
CapyFin.com Forward Guidance
The company reaffirmed its fiscal 2025 outlook for sales, adjusted earnings, and cash flow, expecting supply chain challenges to gradually improve and enable full-year adjusted EPS growth of 5% to 6%.
Positive Outlook
- Reaffirming fiscal 2025 outlook for sales.
- Reaffirming fiscal 2025 outlook for adjusted earnings.
- Reaffirming fiscal 2025 outlook for cash flow.
- Consumption remains healthy for the portfolio.
- Supply chain challenges are expected to gradually improve.
Challenges Ahead
- Supply chain challenges impacted Q1 revenues.
- Revenue decreased 4.4% from the prior year.
- Clear Eyes supply was limited.
- Cough & Cold category declined.
- Women’s Health category declined.
Revenue & Expenses
Visualization of income flow from segment revenue to net income